JCR Pharmaceuticals Co., Ltd. announced appointment of Pascal Yoshida, M.D. as Senior Director, Head of Medical Affairs Unit, effective from July 1, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
581 JPY | +1.22% | +3.75% | -50.43% |
05-31 | JCR Pharmaceuticals' Full-Year Profit Up 46% | MT |
05-27 | Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.43% | 456M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit